Theravance Biopharma Stock Target Price
| TBPH Stock | USD 10.90 0.26 2.33% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Theravance Biopharma's long-term financial health and intrinsic value.
Theravance | Build AI portfolio with Theravance Stock |
Theravance Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Theravance Biopharma's direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Theravance Biopharma could also be used in its relative valuation, which is a method of valuing Theravance Biopharma by comparing valuation metrics of similar companies.Theravance Biopharma is currently under evaluation in target price category among its peers.
Theravance Fundamentals
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.0798 | ||||
| Profit Margin | (0.89) % | ||||
| Operating Margin | (0.94) % | ||||
| Current Valuation | 462.32 M | ||||
| Shares Outstanding | 50 M | ||||
| Shares Owned By Insiders | 4.48 % | ||||
| Shares Owned By Institutions | 91.78 % | ||||
| Number Of Shares Shorted | 3.95 M | ||||
| Price To Earning | (6.20) X | ||||
| Price To Book | 3.28 X | ||||
| Price To Sales | 8.35 X | ||||
| Revenue | 64.38 M | ||||
| Gross Profit | 28.02 M | ||||
| EBITDA | (38.45 M) | ||||
| Net Income | (56.42 M) | ||||
| Cash And Equivalents | 132.85 M | ||||
| Cash Per Share | 1.74 X | ||||
| Total Debt | 49.82 M | ||||
| Debt To Equity | 652.20 % | ||||
| Current Ratio | 4.74 X | ||||
| Book Value Per Share | 3.32 X | ||||
| Cash Flow From Operations | (11.54 M) | ||||
| Short Ratio | 18.03 X | ||||
| Earnings Per Share | (1.18) X | ||||
| Price To Earnings To Growth | (0.05) X | ||||
| Target Price | 17.2 | ||||
| Number Of Employees | 97 | ||||
| Beta | -0.018 | ||||
| Market Capitalization | 545.01 M | ||||
| Total Asset | 354.16 M | ||||
| Retained Earnings | (965.52 M) | ||||
| Working Capital | 128.98 M | ||||
| Current Asset | 237.47 M | ||||
| Current Liabilities | 49.47 M | ||||
| Net Asset | 354.16 M |
About Theravance Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Theravance Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Theravance Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Theravance Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Theravance Biopharma Piotroski F Score and Theravance Biopharma Altman Z Score analysis. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.